Search

Your search keyword '"Littlejohn, Margaret"' showing total 225 results

Search Constraints

Start Over You searched for: Author "Littlejohn, Margaret" Remove constraint Author: "Littlejohn, Margaret"
225 results on '"Littlejohn, Margaret"'

Search Results

4. SAT-377 CRISPR-Cas13b-mediated suppression of hepatitis B surface antigen-pre-clinical investigations of a new therapeutic approach

9. Clinical stage drugs targeting inhibitor of apoptosis proteins purge episomal Hepatitis B viral genome in preclinical models

10. Hepatitis B genotypes in Aboriginal and Torres Strait Islander Australians: correlation with clinical course and implications for management.

12. Hepatitis B genotypes in Aboriginal and Torres Strait Islander Australians: correlation with clinical course and implications for management

13. Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants

15. Molecular epidemiology of hepatitis B among Indigenous Australians in Queensland and the Torres Strait Islands.

18. Hepatitis B virus haplotype number at baseline is a predictive marker of functional cure during antiviral therapy for patients with genotypes A and D HBeAg ‐positive chronic hepatitis B

19. Hepatitis B Virus Flares After Nucleot(s)ide Analogue Cessation Are Associated With Activation of Toll-Like Receptor Signaling Pathways

22. Hepatitis B virus splice variants are associated with reduced likelihood of functional cure and differ across phases of chronic hepatitis B infection

23. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B

24. Hepatitis B virus haplotype number at baseline is a predictive marker of functional cure during antiviral therapy for patients with genotypes A and D HBeAg‐positive chronic hepatitis B.

27. Stopping nucleot(s)ide analogues in non‐cirrhotic HBeAg‐negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels

28. Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity

32. Analysis of Hepatitis B Virus Haplotype Diversity Detects Striking Sequence Conservation Across Genotypes and Chronic Disease Phase

34. Hepatitis B Virus (Hbv) Splice Variants are Associated with Reduced Likelihood of Functional Cure and Differ Across Phases of Chronic Hepatitis B Infection

41. Analysis of HBV full-genome haplotypes from immune tolerant-, immune clearance-, and immune resolution phase of chronic hepatitis B virus disease

42. HBV variants are common in the ‘immune‐tolerant’ phase of chronic hepatitis B

44. Point of care and oral fluid hepatitis B testing in remote Indigenous communities of northern Australia

47. Evaluation of dried blood spots for hepatitis B and D serology and nucleic acid testing.

48. Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance

Catalog

Books, media, physical & digital resources